Monitoring Schistosome Hybrids Under Under Praziquantel Pressure

Schistosomiasis Clinical Trial

— Sen_hybrids  

Official title:

Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04635553
• Other study ID #: SEN2020-BS
• Status: Recruiting
• Start date: August 11, 2020
• Est. completion date: December 31, 2022

Study information

• Verified date: September 2020
• Source: Institut de Recherche pour le Developpement
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overall objective of this project is to examine and quantify the potential existence and impact on Praziquantel (PZQ) efficacy, of naturally occurring S. haematobium and S. bovis hybrid populations in northern Senegal. Schistosome hybrids may present vigor compared to their pure parental forms and hence, may be less sensitive to PZQ. We hypothesise that PZQ repeated treatment selects the hybrid schistosome populations.

Description:

Human schistosomiasis is a Neglected Tropical Disease caused by schistosome helminth worms with impressive epidemiological statistics associated: 800 million people at risk in 78 countries, > 230 million infected and > 200 000 deaths each year. The disease is highly endemic in sub-Saharan Africa where it persists despite mass drug administration with Praziquantel (PZQ). Some schistosomes are specific to humans and induce two main disease forms (either mesenteric or uro-genital) while others are associated with wild animals. However, hybridization can occur between different schistosome species. In northern Senegal, hybridization between schistosome species specific to humans and animals is now known to be frequent with the potential risk of zoonotic transmission. This study will propose an integrative approach by conducting parasitological and molecular analysis including, schistosome miracidia genotyping to show if PZQ repeated treatment affects the genomic composition (Frequencies of alleles) of hybrid populations. The objectives are: - Determine the current prevalence of potential hybrid schistosome populations in their natural setting in Senegal - Determine the sensitivity of hybrid schistosomes to praziquantel treatment in field populations - Determine the molecular basis (at the genome level) of such phenotypic changes). The study is a longitudinal observation of a cohort of school children after repeated Praziquantel (40 mg/kg) treatment, a drug commonly used through Mass Drug Administration (MDA) to treat schistosomiasis. The cohort will be followed over a period of three years. Before the followup, a baseline urogenital schistosomiasis test will be performed on 1, 450 school-age children randomly selected in the five sites (290 in each site). All positive children will receive a single treatment (T1) of Praziquantel (PZQ) (40 mg/kg). Among those who test positive for S. haematobium eggs, only 50 in each site (five sites), who meet all the eligibility criteria will be invited to participate to the longitudinal follow-up. Four rounds of a single praziquantel (PZQ) treatment will be administered to positive individuals every 6 months. One round will consist of one treatment (T1 to T4) followed by a control treatment after one month (CT1 to CT4), hence, before the potential re-infecting schistosomes become adults and start egg-laying, which could bias the effectiveness of treatment evaluations. At each CT time, samples will be collected and S. haematobium eggs quantified (number of excreted eggs/10 mls of urine). Parasites (miracidia hatched from excreted eggs) will be recovered before each initial treatment (T1 to T4) and at CT1 to CT4 for subsequent genetic analysis to characterize hybrid schistosomes between S. haematobium and S. bovis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: December 31, 2022
• Est. primary completion date: July 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Years to 10 Years

Eligibility

Inclusion Criteria:

• Children between the initiation courses (CI) and elementary course second year (CE2)
• Absence of declared chronic pathologies that could impact the follow-up
• Be positive for S. haematobium infection during the selection period (excreting eggs)
• Residing in the study area during the 3 years of the follow-up

Exclusion Criteria:

• Absence of written informed consent or expressed refusal from the child
• Enrolled in another on going study, which implicates the administration of PZQ or tests another product.

Related Conditions & MeSH terms

• Schistosomiasis

Intervention

Drug:
• Praziquantel 600 milligram
A single treatment with a dose of 40 milligram/kilogram (mg/kg)

Locations

Country	Name	City	State
Senegal	Bruno SENGHOR	Dakar

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Recherche pour le Developpement

Country where clinical trial is conducted

Senegal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in prevalence and intensity of schistosome infection	Determine at the 1 month post treatment the cure rate (CR) of the treatments and Egg Reduction Rates (ERR).	December 31. 2020
Secondary	Hybrids tolerance to praziquantel	The frequency of hybrids and the level of genomic introgression between S. bovis and S. haematobium	December 31, 2021